Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake
This may be due to a browser extension, network issues, or browser settings
Simultaneous engagement of GLP-1, GIP, and glucagon receptors Modulation of integrated metabolic signaling networks Effects on energy homeostasis pathways Interaction with endocrine feedback systems Participation in glucose and lipid metabolism models Influence on appetite-related neuroendocrine signaling Why it matters: Multi-receptor activity may help explain why Retatrutide is studied differently from single-pathway GLP-1 compounds
Moving forward, the results of the phase 3 SURPASS clinical trial program demonstrated that tirzepatide was as effective and safe as other anti-diabetic agents, such as semaglutide and dulaglutide (SURPASS-2) (SURPASS J-mono), long-acting insulin analogs (degludec and glargine) (SURPASS-3,4), and placebo (SURPASS-1) (SURPASS-5), in managing T2DM diabetes [65,66,67,68,69]
When standard weekly dosing is the better choice For most researchers, standard weekly dosing remains the superior option
